Biocon

Why is Biocon Ltd. falling/rising?

As of 09-Aug, Biocon Ltd. is experiencing a stock price decline to Rs 430.00, reflecting a -1.71% change. Despite this, the stock has shown positive long-term performance and remains supported by strong fundamentals and institutional backing.

As of 09-Aug, Biocon Ltd. is experiencing a decline in its stock price, currently at Rs 430.00, which reflects a change of -7.5 or -1.71%. Despite this drop, the stock has shown positive performance over various periods, including a 1-week increase of 1.02% and a 1-month increase of 5.68%. However, today's performance indicates that it has underperformed its sector by 1.83%, and it touched an intraday low of Rs 425.4, which is a decrease of 2.77%.<BR><BR>The stock is currently trading close to its 52-week high, being only 3.95% away from Rs 447. This suggests that while there is potential for recovery, the recent price movement indicates some selling pressure. Additionally, while the stock has a strong long-term performance, with a 17.94% return over the past year and significant profit growth of 140%, the current decline may be influenced by short-term market dynamics or profit-taking by investors.<BR><BR>Despite the current drop, Biocon Ltd. maintains a favorable valuation with a return on capital employed (ROCE) of 3.3 and a PEG ratio of 0.8, indicating that it is trading at a discount compared to its peers. Furthermore, high institutional holdings at 31.53% suggest that knowledgeable investors are backing the stock, which could provide some support against further declines. Overall, while the stock is currently falling, its long-term fundamentals remain strong, which may attract investors looking for value.

Which are the latest news on Biocon?

Should I buy, sell or hold Biocon Ltd.?

When is the next results date for Biocon Ltd.?

The next results date for Biocon Ltd. is August 5, 2026.

The next results date for Biocon Ltd. is scheduled for August 5, 2026.

How big is Biocon?

As of 10th June, Biocon Ltd. has a market capitalization of 67,333.00 Cr and reported net sales of 16,927.00 Cr and a net profit of 385.60 Cr over the latest four quarters.

As of 10th June, <BR><BR>Market Cap: Biocon Ltd. has a market capitalization of 67,333.00 Cr, categorizing it as a Mid Cap company.<BR><BR>Recent Quarterly Performance: The sum of Net Sales for the latest 4 quarters is 16,927.00 Cr, while the sum of Net Profit for the same period is 385.60 Cr.<BR><BR>Balance Sheet Snapshot: The reporting period for the latest annual data is March 2025. Shareholder's Funds stand at 21,644.00 Cr, and Total Assets are valued at 58,539.60 Cr.

Who are in the management team of Biocon?

The management team of Biocon includes Chairperson Kiran Mazumdar Shaw, Managing Director & CEO Siddharth Mittal, and Directors Ravi Mazumdar and Eric Vivek Mazumdar, along with Company Secretary Mayank Verma. The board also features independent directors such as Vijay Kumar Kuchroo and Naina Lal Kidwai, among others.

The management team of Biocon includes the following key individuals:<BR><BR>1. **Kiran Mazumdar Shaw** - Chairperson<BR>2. **Siddharth Mittal** - Managing Director & CEO<BR>3. **Ravi Mazumdar** - Director<BR>4. **Eric Vivek Mazumdar** - Director<BR>5. **Mayank Verma** - Company Secretary & Compliance Officer<BR><BR>Additionally, the board features several independent directors:<BR>- **Vijay Kumar Kuchroo**<BR>- **M Damodaran**<BR>- **Bobby Parikh**<BR>- **Naina Lal Kidwai**<BR>- **Peter John Bains**<BR><BR>This team brings a diverse range of expertise to Biocon, contributing to its leadership in the biopharmaceutical sector.

Who are the peers of the Biocon?

Biocon's peers include Dr Reddy's Labs, Lupin, Mankind Pharma, Aurobindo Pharma, and others. Biocon has average management risk, below average growth, and a below average capital structure, with a 1-year return of 16.70%, lower than Aurobindo Pharma's 26.39% but higher than Abbott India's -16.53%.

Peers: The peers of Biocon are Dr Reddy's Labs, Lupin, Mankind Pharma, Aurobindo Pharma, Laurus Labs, Alkem Lab, Glenmark Pharma, Abbott India, Anthem Bioscienc, and Ipca Labs.<BR><BR>Quality Snapshot: Excellent management risk is observed at Dr Reddy's Labs, Lupin, Mankind Pharma, Alkem Lab, Glenmark Pharma, Abbott India, and Anthem Bioscienc, while Average management risk is found at Aurobindo Pharma, Laurus Labs, Biocon, and Ipca Labs. Growth is rated as Excellent for Lupin, Mankind Pharma, and Anthem Bioscienc, while Below Average growth is noted for Aurobindo Pharma, Laurus Labs, Biocon, and Ipca Labs, with the rest showing Average growth. Capital Structure is Excellent for Dr Reddy's Labs, Mankind Pharma, Aurobindo Pharma, Alkem Lab, Abbott India, and Anthem Bioscienc, while Below Average capital structure is noted for Biocon, with Average capital structure at Laurus Labs and the rest showing Good capital structure.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Aurobindo Pharma at 26.39%, while Abbott India has the lowest at -16.53%. Biocon's own 1-year return is 16.70%, which is significantly higher than Abbott India's but lower than Aurobindo Pharma's. Additionally, Alkem Lab, Abbott India, and Glenmark Pharma have negative six-month returns.

What does Biocon do?

Biocon Ltd. is India's largest biopharmaceutical company, specializing in biotechnology products and research services. As of March 2026, it reported net sales of ₹4,517 Cr and a net profit of ₹126 Cr, with a market cap of ₹67,333 Cr.

Overview:<BR>Biocon Ltd. is India's largest and fully-integrated, innovation-led biopharmaceutical company operating in the Pharmaceuticals & Biotechnology industry within the mid-cap market segment.<BR><BR>History:<BR>Biocon Limited was incorporated in 1978 as a joint venture between Biocon Biochemicals Limited of Ireland and Indian entrepreneur Kiran Mazumdar-Shaw. The company has evolved to manufacture and export biotechnology products and research services. The latest reported quarterly results show net sales and profit for the period ending March 2026.<BR><BR>Financial Snapshot:<BR>- Net Sales: 4,517 Cr (Quarterly Results - Mar 2026)<BR>- Net Profit: 126 Cr (Quarterly Results - Mar 2026)<BR>- Market Cap: INR 67,333 Cr (Mid Cap)<BR><BR>Key Metrics:<BR>- P/E: 89.00<BR>- Industry P/E: 34<BR>- Dividend Yield: 0.10%<BR>- Debt Equity: 0.34<BR>- Return on Equity: 2.21%<BR>- Price to Book: 1.98<BR><BR>Contact Details:<BR>- Address: 20th KM Hosur Road Hebbagodi, Electronic City P O Bangalore Karnataka : 560100<BR>- Tel: 91-80-28082808<BR>- Email: co.secretary@biocon.com<BR>- Website: http://www.biocon.com

Are Biocon Ltd. latest results good or bad?

Biocon Ltd.'s latest Q4 FY26 results show record net sales of ₹4,516.60 crores, but net profit fell 63.45% to ₹125.90 crores, indicating significant operational challenges and declining profitability metrics. Overall, the results lean towards the negative side despite revenue growth.

Biocon Ltd.'s latest results for Q4 FY26 present a mixed picture, but overall, they lean towards the negative side. While the company achieved record net sales of ₹4,516.60 crores, reflecting a year-on-year growth of 2.25% and an impressive sequential increase of 8.23%, this top-line growth did not translate into profitability. The net profit for the quarter plummeted to ₹125.90 crores, marking a significant decline of 63.45% compared to the same quarter last year.<BR><BR>Additionally, the operating margin decreased to 22.75%, down 199 basis points from the previous year, indicating rising operational costs and inefficiencies. The PAT margin also fell sharply to 4.43%, down 611 basis points year-on-year, which highlights ongoing profitability challenges.<BR><BR>For the full fiscal year FY26, Biocon reported consolidated net sales of ₹16,927 crores, a modest growth of 3.40% over the previous year. However, the company's return on equity (ROE) has dropped to a concerning 1.74%, significantly below industry averages, suggesting that the company is struggling to generate adequate returns for shareholders.<BR><BR>In summary, while Biocon's revenue growth is a positive aspect, the substantial decline in net profit and profitability metrics indicates serious operational challenges that the company needs to address.

How has been the historical performance of Biocon?

Biocon has shown consistent growth in net sales and profits, with net sales increasing from 5,514.40 Cr in Mar'19 to 15,261.70 Cr in Mar'25, and profit after tax rising to 1,429.40 Cr. Total assets grew significantly to 58,539.60 Cr, while total debt also increased, indicating higher financial leverage.

Answer:<BR>The historical performance of Biocon shows a consistent growth trajectory in net sales and profits over the years, with net sales increasing from 5,514.40 Cr in Mar'19 to 15,261.70 Cr in Mar'25. The total operating income followed a similar trend, rising from 5,514.40 Cr in Mar'19 to 15,261.70 Cr in Mar'25. Operating profit (PBDIT) also saw a significant increase, reaching 4,374.50 Cr in Mar'25 from 1,538.10 Cr in Mar'19. Profit before tax rose to 1,886.60 Cr in Mar'25, compared to 1,214.00 Cr in Mar'19, while profit after tax increased to 1,429.40 Cr from 1,001.70 Cr in the same period. The earnings per share (EPS) fluctuated, peaking at 8.52 in Mar'24 before slightly declining to 8.44 in Mar'25. The company's total assets grew from 14,075.80 Cr in Mar'20 to 58,539.60 Cr in Mar'25, indicating a robust expansion. However, total debt also increased from 1,154.20 Cr in Mar'20 to 15,860.10 Cr in Mar'25, reflecting a rise in financial leverage. The cash flow from operating activities improved significantly, reaching 4,061.00 Cr in Mar'25, up from 1,283.00 Cr in Mar'20, contributing to a net cash inflow of 2,004.00 Cr in Mar'25.<BR><BR>Breakdown:<BR>Biocon's financial performance over the years demonstrates a strong upward trend in both revenue and profitability. Net sales surged from 5,514.40 Cr in Mar'19 to 15,261.70 Cr in Mar'25, while total operating income mirrored this growth. Operating profit (PBDIT) increased significantly, reaching 4,374.50 Cr in Mar'25, reflecting effective cost management despite rising raw material and employee costs. Profit before tax also saw a notable rise to 1,886.60 Cr in Mar'25, with profit after tax following suit at 1,429.40 Cr. The company's EPS showed variability, peaking at 8.52 in Mar'24 before slightly declining. Total assets expanded dramatically from 14,075.80 Cr in Mar'20 to 58,539.60 Cr in Mar'25, while total debt rose concurrently, indicating increased leverage. Cash flow from operating activities improved significantly, culminating in a net cash inflow of 2,004.00 Cr in Mar'25, showcasing the company's strong operational performance.

How has been the historical performance of Biocon?

Biocon has demonstrated consistent growth in net sales and profits, with net sales increasing from INR 5,514.40 crore in March 2019 to INR 15,261.70 crore in March 2025, and profit after tax rising from INR 1,001.70 crore to INR 1,429.40 crore during the same period, despite a slight decline in operating profit margin. Total assets grew significantly, reflecting strong overall financial performance.

Answer:<BR>The historical performance of Biocon shows a consistent growth trajectory in net sales and profits over the years.<BR><BR>Breakdown:<BR>Biocon's net sales have increased significantly from INR 5,514.40 crore in March 2019 to INR 15,261.70 crore in March 2025, reflecting a robust growth trend. The total operating income followed a similar pattern, rising from INR 5,514.40 crore in March 2019 to INR 15,261.70 crore in March 2025. The company's operating profit (PBDIT) also demonstrated a positive trend, climbing from INR 1,538.10 crore in March 2019 to INR 4,374.50 crore in March 2025. However, the operating profit margin has seen a slight decline from 25.27% in March 2019 to 21.04% in March 2025. Profit after tax has increased from INR 1,001.70 crore in March 2019 to INR 1,429.40 crore in March 2025, with a PAT margin of 9.5% in March 2025. On the balance sheet, total assets rose from INR 14,075.80 crore in March 2020 to INR 58,539.60 crore in March 2025, while total liabilities increased from INR 14,075.80 crore to INR 15,860.10 crore over the same period. The cash flow from operating activities improved significantly, reaching INR 4,061.00 crore in March 2025, compared to INR 1,283.00 crore in March 2020. Overall, Biocon has shown strong growth in sales, profits, and cash flow, indicating a solid financial performance over the years.

Is Biocon technically bullish or bearish?

As of October 30, 2025, Biocon's trend has shifted to bullish with moderate strength, supported by bullish daily moving averages and Bollinger Bands, though caution is advised due to a mildly bearish MACD on the weekly chart.

As of 30 October 2025, the technical trend for Biocon has changed from mildly bullish to bullish. The current stance is bullish with moderate strength. Key indicators driving this include the daily moving averages which are bullish, and the Bollinger Bands showing bullish signals on both weekly and monthly time frames. However, the MACD on the weekly is mildly bearish, which suggests some caution. Overall, the bullish trend is supported by strong performance relative to the Sensex, particularly over the past month and year.

Is Biocon overvalued or undervalued?

As of September 9, 2025, Biocon is considered overvalued with a PE ratio of 139.57, significantly higher than its peers, and despite recent stock performance outpacing the Sensex, it has declined 3.29% over the past year, indicating a shift in valuation from very attractive to attractive.

As of 9 September 2025, Biocon's valuation grade has moved from very attractive to attractive, indicating a shift in perception regarding its market position. The company appears to be overvalued, with a PE ratio of 139.57, significantly higher than its peers such as Cipla at 23.28 and Dr. Reddy's Labs at 18.99, which are both categorized as attractive. Additionally, Biocon's EV to EBITDA stands at 19.15, while its PEG ratio is notably at 0.00, suggesting limited growth expectations relative to its current valuation.<BR><BR>In comparison to its peers, Biocon's financial metrics highlight a disparity; for instance, Sun Pharma has a PE ratio of 33.36, categorized as expensive, while Divi's Lab is deemed very expensive with a PE of 69.19. The company's recent stock performance has outpaced the Sensex over the past week and month, with returns of 2.76% and 6.20%, respectively. However, the longer-term view shows a decline of 3.29% over the past year, contrasting with the Sensex's minor drop of 0.56%. This further supports the conclusion that Biocon is currently overvalued in the market.

Who are the top shareholders of the Biocon?

The top shareholders of Biocon include Kiran Mazumdar Shaw, who holds 36.24%, followed by mutual funds at 13.82%, foreign institutional investors at 7.0%, and individual investors at 13.08%. The largest public shareholder is the LICI Ulip-Growth Fund with 4.83%.

The top shareholders of Biocon include the promoters, who hold the majority of the shares. Kiran Mazumdar Shaw is the promoter with the highest holding, owning 36.24% of the company. Additionally, mutual funds hold 13.82% of the shares across 30 schemes, while foreign institutional investors (FIIs) hold 7.0% through 296 different entities. The highest public shareholder is the LICI Ulip-Growth Fund, which holds 4.83%. Individual investors collectively own 13.08% of the shares.

What is the bonus history of the Biocon?

Biocon has issued bonuses on three occasions: a 1:1 bonus on June 12, 2019, a 2:1 bonus on June 15, 2017, and another 1:1 bonus on September 11, 2008, rewarding shareholders over the years.

Biocon has a history of bonus issues that includes the following:<BR><BR>1. On June 12, 2019, Biocon announced a 1:1 bonus issue, with the record date set for June 13, 2019.<BR>2. Prior to that, on June 15, 2017, the company issued a 2:1 bonus, with the record date on June 17, 2017.<BR>3. Additionally, on September 11, 2008, Biocon had a 1:1 bonus issue, with the record date on September 12, 2008.<BR><BR>This reflects Biocon's approach to rewarding shareholders through bonus shares over the years.

Has Biocon declared dividend?

Yes, Biocon Ltd. has declared a 10% dividend, amounting to ₹0.5 per share, with an ex-date of July 5, 2024. While the company has shown mixed total returns across different periods, it recorded a total return of 36.41% over the last 2 years.

Biocon Ltd. has declared a 10% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 10%<BR>- Amount per share: 0.5<BR>- Ex-date: 05 Jul 24<BR><BR>Dividend Yield: 0.15%.<BR><BR>Total Returns by Period:<BR>In the last 6 months, the price return was -12.96%, the dividend return was 0%, resulting in a total return of -12.96%.<BR><BR>Over the past year, the price return was -0.83%, the dividend return was 0.15%, leading to a total return of -0.68%.<BR><BR>In the 2-year period, the price return was 35.59%, the dividend return was 0.82%, which resulted in a total return of 36.41%.<BR><BR>For the 3-year period, the price return was 3.4%, the dividend return was 0.80%, culminating in a total return of 4.2%.<BR><BR>In the last 4 years, the price return was -14.24%, the dividend return was 0.62%, resulting in a total return of -13.62%.<BR><BR>Over the past 5 years, the price return was -15.32%, the dividend return was 0.64%, leading to a total return of -14.68%.<BR><BR>Overall, Biocon has declared a dividend, but the total returns over various periods show a mixed performance, with significant negative returns in the shorter terms and a positive return over the 2-year period.